Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17986918 | 1.00 | SMN1; SMN2 (0.37) | SMN1; SMN2CA14CA12ACHECA1 | |
| SCHEMBL17986909 | 1.00 | SMN1; SMN2 (0.37) | SMN1; SMN2CA14CA12ACHECA1 | |
| Hydrochloric Acid SCHEMBL35210724 | 0.98 | SMN1; SMN2 (0.35) | SMN1; SMN2CA14CA12ACHECA1 | |
| SCHEMBL2889933 | 0.80 | SMN1; SMN2 (0.36) | SMN1; SMN2CA14ACHECA1CA2 | |
| SCHEMBL2886731 | 0.80 | SMN1; SMN2 (0.36) | SMN1; SMN2CA14ACHECA1CA2 | |
| SCHEMBL3906700 | 0.79 | ALOX15 (0.38) | — | |
| SCHEMBL15534315 | 0.79 | ALOX15 (0.38) | — | |
| SCHEMBL6818897 | 0.77 | SMN1; SMN2 (0.39) | SMN1; SMN2CA14CA12ACHECA1 | |
| Trifluoroacetic Acid SCHEMBL3209972 | 0.75 | SLC7A5 (0.43) | SMN1; SMN2CA14CA12SLC1A3SLC1A2 | |
| Trifluoroacetic Acid SCHEMBL3209975 | 0.75 | SLC7A5 (0.43) | SMN1; SMN2CA14CA12SLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257388-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230257388-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-11667645-B2 | Granzyme B directed imaging and therapy | CYTOSITE BIOPHARMA INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667645-B2 | Granzyme B directed imaging and therapy | CYTOSITE BIOPHARMA INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20200369673-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC. | 2020-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257388-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | GZMB, PRF1, CTSB | SMN1; SMN2 1756/4885CA14 486/4885CA12 724/4885 |
| US-20200369673-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | GZMB, PRF1, CTSB | SMN1; SMN2 1756/4885CA14 486/4885CA12 724/4885 |
| US-11667645-B2 | Granzyme B directed imaging and therapy | GZMB, PRF1, CTSB | SMN1; SMN2 1756/4885CA14 486/4885CA12 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.